Ignite Creation Date:
2025-12-25 @ 2:14 AM
Ignite Modification Date:
2026-01-08 @ 5:07 AM
Study NCT ID:
NCT02402660
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2025-04-27
First Post:
2015-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Sponsor:
Alkeus Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-08
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2015-03-09
First Submit QC Date:
None
Study First Post Date:
2015-03-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-24
Last Update Post Date:
2025-04-27
Last Update Post Date Type:
ACTUAL